Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
751 participants in 2 patient groups
There are currently no registered sites for this trial.
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Start date
Apr 21, 2023 • 2 years ago
End date
Nov 13, 2024 • 5 months ago
Today
May 10, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal